CytoReason

The volume of human molecular data is growing exponentially, but our analytic capabilities are growing linearly, at best. Humans alone cannot process all this data. What’s needed is a technology capable of digesting, organizing and making sense of all data types and sources. We founded CytoReason in 2016 to address this problem. Our computational disease models are designed to gather impossible amounts of data from countless indications and treatments. They tell you which genes are active, in which cells, within which pathways, and across which diseases, patients, and drugs. `CytoReason’s biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective,” said Mikael Dolsten, M.D., Ph.D., Pfizer’s chief scientific officer and president of the worldwide research, development and medical division.